Breast Cancer
Conditions
Keywords
breast cancer, autotaxin, tumor marker
Brief summary
The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients. The main questions it aims to answer are; * is ATX a reliable tumor marker for breast cancer patients in diagnosis * can ATX differentiate cancer patients from non-cancer ones
Detailed description
80 breast cancer patients and 30 normal patients with no known cancer history were enrolled in this study. All patients were female. The mean ages of cancer patients were 58.2 and 52.7 consecutively for cancer and non-cancer patients. The mean serum ATX levels of cancer and non-cancer patients were 1570.72 and 121.86 ng/mL consecutively (p=0.001). The cut-off value of ATX serum level was 178.49ng/mL according to the ROC analysis. The area under the ROC curve was 0.901showing that ATX is very efficient in distinguishing between two diagnostic groups (diseased/normal). ATX also showed good correlations with known tumor markers (CEA, CA15-3, CA125 levels). ATX levels were still higher than the cut-off value even in cancer patients with normal or low classical tumor marker levels.
Interventions
BIOLOGICALmeasurement of serum autotaxin serum level
autotaxin expression
Sponsors
Diskapi Yildirim Beyazit Education and Research Hospital
Ankara Etlik City Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Preoperatively diagnosed breast cancer patients with no synchronous cancer and without known hepatic or other inflammatory disorders.
Exclusion criteria
* Patients with benign breast diseases and no known cancer history.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Autotaxin as a tumor marker | preoperative period | Diagnostic value of Autotaxin in breast cancer |
Countries
Turkey (Türkiye)
Outcome results
None listed